How Global Investors Structure, Finance & Acquire Australian Biotech

Biotech is no longer a fringe asset class it’s a frontier of global capital deployment, strategic acquisitions, and high-growth innovation.

But investing in biotech isn’t just about believing in a breakthrough it’s about structuring deals correctly, managing cross border capital flows, and avoiding the pitfalls that destroy value.

If you're a family office, institutional investor, wealth manager, strategic buyer, or sophisticated individual investor considering biotech opportunities especially in the Asia Pacific this session is for you.

This exclusive briefing brings together deal practitioners with deep operational exposure in structuring, financing, and acquiring biotech assets including those with real, in-flight deals today.

Why Attend

Investors face four critical execution gaps:

✅ Deal structure and cross-border capital architecture
✅ Legal, regulatory, and tax guardrails in Australia & APAC
✅ Financing strategy including global capital sourcing
✅ Due diligence processes that actually protect capital

This session provides real-world, execution-level insight from experts who live and breathe cross-border deals.

🎙 Keynote Speakers

Roy Ong

Family Office Advisor | Cross-Border M&A & Capital Structuring Specialist | Singapore

Roy advises ultra-high net-worth families and institutional capital on cross-border acquisitions and strategic investments across APAC. With over 30 years in finance and deal structuring, he has led transactions in the nine-figure range, specializing in biotech, healthcare, and strategic expansion plays.

He brings real-world insight into:

• Structuring international biotech acquisitions
• Family office investment strategy
• Capital sourcing across Asia (Japan, Singapore, China, EU)
• Due diligence frameworks for high-risk sectors

Wei Ping Lee

Australian Lawyer | Cross-Border Investment & Corporate Structuring

Wei Ping Lee is a seasoned Australian corporate and investment lawyer with deep expertise in cross-border capital flows, foreign investment compliance, corporate structuring and risk mitigation. Based between Sydney and APAC markets, Bill regularly advises both local and international investors on navigating legal and regulatory frameworks particularly in sectors like biotech, health tech, and high-growth industries.

He brings practical insight into:

• Legal frameworks for acquiring biotech assets in Australia
• Foreign investment structures and compliance
• Corporate governance and risk mitigation
• Real deal-stage legal issues investors encounter